Dr. Sharon F Freedman, MD
Claim this profileDuke University Eye Center
Studies Retinal Disease
Studies Premature Birth
5 reported clinical trials
5 drugs studied
Area of expertise
1Retinal Disease
Stage II
Stage III
2Premature Birth
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Sharon F Freedman, MD is currently running
Bevacizumab
for Retinopathy of Prematurity
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Recruiting1 award Phase 22 criteria
High-Speed Eye Scanning Technology
for Retinopathy of Prematurity
Retinopathy of prematurity (ROP) is a disorder of development of the neural retina and its vasculature that can impact vision in vulnerable preterm neonates for a lifetime. This study tests high-speed optical coherence tomography (OCT) technology compared to conventional color photographs at the bedside of very preterm infants in the intensive care nursery, to characterize previously unseen abnormalities that can predict a need for referral for ROP treatment, or poor visual or neurological development later in life, up to pre-school age. Our long-term goal is to help improve preterm infant health and vision via objective bedside imaging and analysis that characterizes early critical indicators of ROP, and poor visual function and neurological development, which will rapidly translate to better early intervention and improved future care.
Recruiting1 award N/A
More about Sharon F Freedman, MD
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sharon F Freedman, MD has experience with
- Bevacizumab
- Laser
- Swept Source OCT
- Investigational Ultracompact OCT And OCTA System
- Retinal Photographs
Breakdown of trials Sharon F Freedman, MD has run
Retinal Disease
Premature Birth
Retinopathy of Prematurity
Macular Edema
Neurodevelopmental Disorders
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sharon F Freedman, MD specialize in?
Sharon F Freedman, MD focuses on Retinal Disease and Premature Birth. In particular, much of their work with Retinal Disease has involved Stage II patients, or patients who are Stage III.
Is Sharon F Freedman, MD currently recruiting for clinical trials?
Yes, Sharon F Freedman, MD is currently recruiting for 2 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Sharon F Freedman, MD has studied deeply?
Yes, Sharon F Freedman, MD has studied treatments such as Bevacizumab, Laser, Swept Source OCT.
What is the best way to schedule an appointment with Sharon F Freedman, MD?
Apply for one of the trials that Sharon F Freedman, MD is conducting.
What is the office address of Sharon F Freedman, MD?
The office of Sharon F Freedman, MD is located at: Duke University Eye Center, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke University Eye Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.